Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Leerink Partners
Equities research analysts at Leerink Partners assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage set an “underperform” rating and a $12.00 price target on the stock. Leerink Partners’ price target would indicate a potential downside of 40.48% from […]
Equities research analysts at Leerink Partners assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage set an “underperform” rating and a $12.00 price target on the stock. Leerink Partners’ price target would indicate a potential downside of 40.48% from […]
